SEARCH:   Advanced

Blood, 15 November 2005, Vol. 106, No. 10, pp. 3380-3382. Prepublished online as a Blood First Edition Paper on August 2, 2005; DOI 10.1182/blood-2005-01-0335. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-01-0335v1 106/10/3380    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mone, A. Articles by Porcu, P. Search for Related Content PubMed PubMed Citation Articles by Mone, A. Articles by Porcu, P. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-–refractory adult T-cell leukemia Andrew Mone, Shannon Puhalla, Susan Whitman, Robert A. Baiocchi, Julio Cruz, Tamara Vukosavljevic, Amy Banks, Charles F. Eisenbeis, John C. Byrd, Michael A. Caligiuri, and Pierluigi Porcu From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus. Adult T-cell leukemia (ATL) is a highly chemoresistant and usually fatal T-cell malignancy due to the human T-cell lymphotropic virus-1 (HTLV-1). After chemotherapy failure, antiretrovirals and interferon- (IFN-) produce brief responses followed by progression and death. More effective agents and new approaches to detect and treat minimal residual disease are needed. ATL cells express CD52, the target of the antibody alemtuzumab, which is active in a preclinical model of ATL and is cytotoxic for p53-deficient cells. A patient with refractory chronic ATL in transformation achieved longer than a 1-year complete hematologic response following 12 weeks of outpatient subcutaneous alemtuzumab. Persistent suppression of HTLV-1 viral load, even at recovery of T cells, after alemtuzumab and efficient in vitro complement-mediated cytotoxicity of primary ATL cells with mutated TP53 were observed. The unprecedented response and the profound suppression of HTLV-1 viral load observed in this patient suggest that further clinical investigation of alemtuzumab in ATL is warranted. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E Matutes Adult T-cell leukaemia/lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1373 - 1377. [Abstract] [Full Text] [PDF] A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence Blood, August 1, 2006; 108(3): 1021 - 1029. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020